Spoken Alpha
MIRM
Mirum Pharmaceuticals, Inc.
Overview
Mirum Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $6.77B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0619 Q&A exchanges
- Q4 FY2025Earnings2026-02-2511 Q&A exchanges
- Q3 FY2025Earnings2025-11-0411 Q&A exchanges
- Q2 FY2025Earnings2025-08-0610 Q&A exchanges
- Q1 FY2025Earnings2025-05-0717 Q&A exchanges
- Q4 FY2024Earnings2025-02-2719 Q&A exchanges
- Q3 FY2024Earnings2024-11-1223 Q&A exchanges
- Q1 FY2024Earnings2024-05-0818 Q&A exchanges
- Q4 FY2023Earnings2024-02-2824 Q&A exchanges
- Q3 FY2023Earnings2023-11-0513 Q&A exchanges
- Q2 FY2023Earnings2023-08-0516 Q&A exchanges
- Q1 FY2023Earnings2023-05-0719 Q&A exchanges
- Q4 FY2022Earnings2023-03-0813 Q&A exchanges
- Q3 FY2022Earnings2022-11-0912 Q&A exchanges
- Q2 FY2022Earnings2022-08-076 Q&A exchanges
- Q1 FY2022Earnings2022-05-0714 Q&A exchanges
- Q4 FY2021Earnings2022-03-0913 Q&A exchanges
- Q3 FY2021Earnings2021-11-1621 Q&A exchanges
- Q2 FY2021Earnings2021-08-0817 Q&A exchanges
- Q1 FY2021Earnings2021-05-0918 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $-0.81—Rev— vs ——EODHD
- Q1 FY20262026-05-06EPS$-1.08 vs $-0.35-100.0%Rev$159.9M vs ——EODHD
- Q4 FY20252026-03-10EPS$-0.12 vs $-0.05-100.0%Rev$148.9M vs ——EODHD
- Q3 FY20252025-11-03EPS$0.05 vs $-0.15+100.0%Rev$133.0M vs ——EODHD
- Q2 FY20252025-08-05EPS$-0.12 vs $-0.33+63.6%Rev$127.8M vs ——EODHD
- Q1 FY20252025-05-05EPS$-0.30 vs $-0.48+37.5%Rev$111.6M vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.49 vs $-0.25-98.7%Rev$99.4M vs ——EODHD
- Q3 FY20242024-11-03EPS$-0.30 vs $-0.45+33.8%Rev$90.4M vs ——EODHD
- Q2 FY20242024-08-06EPS$-0.52 vs $-0.47-10.6%Rev$77.9M vs ——EODHD
- Q1 FY20242024-05-07EPS$-0.54 vs $-0.48-12.5%Rev$69.2M vs ——EODHD
- Q4 FY20232024-02-27EPS$-0.66 vs $-0.24-100.0%Rev$69.6M vs ——EODHD
- Q3 FY20232023-11-01EPS$-0.57 vs $-0.63+9.5%Rev$47.7M vs ——EODHD
- Q2 FY20232023-08-02EPS$-1.94 vs $-0.80-100.0%Rev$37.5M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.80 vs $-0.94+14.9%Rev$31.6M vs ——EODHD
- Q4 FY20222023-03-07EPS$-0.99 vs $-1.02+2.9%Rev$27.9M vs ——EODHD
- Q3 FY20222022-11-08EPS$-1.02 vs $-1.07+4.7%Rev$18.8M vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.84 vs $-1.15+27.0%Rev$17.5M vs ——EODHD
- Q1 FY20222022-05-04EPS$-1.17 vs $-1.34+12.7%Rev$12.9M vs ——EODHD
- Q4 FY20212022-03-08EPS$-1.66 vs $0.35-100.0%Rev$3.1M vs ——EODHD
- Q3 FY20212021-11-14EPS$-1.55 vs $-1.73+10.4%Rev$5.0M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $-0.81 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-1.08 | $-0.35 | -100.0% | $159.9M | — | — | EODHD |
| Q4 FY2025 | 2026-03-10 | $-0.12 | $-0.05 | -100.0% | $148.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.05 | $-0.15 | +100.0% | $133.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.12 | $-0.33 | +63.6% | $127.8M | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $-0.30 | $-0.48 | +37.5% | $111.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.49 | $-0.25 | -98.7% | $99.4M | — | — | EODHD |
| Q3 FY2024 | 2024-11-03 | $-0.30 | $-0.45 | +33.8% | $90.4M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.52 | $-0.47 | -10.6% | $77.9M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.54 | $-0.48 | -12.5% | $69.2M | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-0.66 | $-0.24 | -100.0% | $69.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.57 | $-0.63 | +9.5% | $47.7M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-1.94 | $-0.80 | -100.0% | $37.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.80 | $-0.94 | +14.9% | $31.6M | — | — | EODHD |
| Q4 FY2022 | 2023-03-07 | $-0.99 | $-1.02 | +2.9% | $27.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-1.02 | $-1.07 | +4.7% | $18.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.84 | $-1.15 | +27.0% | $17.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-1.17 | $-1.34 | +12.7% | $12.9M | — | — | EODHD |
| Q4 FY2021 | 2022-03-08 | $-1.66 | $0.35 | -100.0% | $3.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-1.55 | $-1.73 | +10.4% | $5.0M | — | — | EODHD |
Source: EODHD. MIRM reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks MIRM's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 9/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.65 | $2.86 | -7.5% | -2.7% | -0.3% |
| Q4 FY2026 | $2.37 | $2.67 | -11.3% | +4.1% | +3.6% |
| Q3 FY2026 | $2.53 | $2.68 | -5.7% | +1.4% | +3.5% |
| Q2 FY2026 | $2.58 | $2.93 | -11.8% | +3.3% | +1.7% |
| Q1 FY2025 | $2.81 | $2.95 | -4.8% | +2.5% | +2.5% |
| Q4 FY2025 | $2.58 | $2.75 | -6.3% | +8.6% | +10.7% |
| Q3 FY2025 | $2.91 | $2.99 | -2.6% | +5.7% | +3.2% |
| Q2 FY2025 | $2.92 | $2.94 | -0.6% | +3.5% | +4.7% |
| Q1 FY2024 | $2.86 | $2.84 | +0.6% | +6.6% | +8.3% |
| Q4 FY2024 | $2.45 | $2.82 | -13.0% | -1.3% | -3.3% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Maintained2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Christopher PeetzCEO7 mo20 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last call held guidance Q3 FY2026
- Eric BjerkholtCFO10 mo10 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Peter RadovichCOO5 mo18 callsCurrentSample
COO since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
- Joanne QuanCHIEF MEDICAL OFFICER5 mo8 callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2026
- Jolanda HoweSVP, GLOBAL CONTROLLER5 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MIRM.
$ curl https://api.spokenalpha.com/v1/companies/MIRMFAQ
Frequently asked about MIRM
Where can I find Mirum Pharmaceuticals, Inc.'s (MIRM) earnings call transcripts?
Spoken Alpha indexes MIRM's earnings call transcripts at https://spokenalpha.com/companies/MIRM. Each call links to attributed speakers and parsed analyst Q&A. Mirum Pharmaceuticals, Inc.'s own investor relations page is at https://ir.mirumpharma.com/overview/default.aspx.
When was Mirum Pharmaceuticals, Inc.'s most recent earnings call?
Mirum Pharmaceuticals, Inc. (MIRM) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
What sector is MIRM in?
Mirum Pharmaceuticals, Inc. (MIRM) operates in the Healthcare sector (Biotechnology industry).